A PHASE II DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE

一项 II 期双盲、随机、安慰剂对照研究来评估

• 批准号: 7606796
• 负责人: RONALD T. MITSUYASU
• 金额: $ 1.44万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-02-21 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7606796
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Double-Blind Method; Funding; Grant; Institution; Interruption; Phase; Placebos; Research; Research Personnel; Resources; Source; United States National Institutes of Health; Vaccines; Viral; Week; randomized placebo controlled trial

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary Objective: To determine if the MRK Ad5 vaccine has an effect of maintaining viral suppression following interruption of ART over 16 weeks post-ART interruption, versus placebo.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 主要目标： 为了确定MRK AD5疫苗是否在16周内中断后与安慰剂相比，在16周内中断ART后是否具有维持病毒抑制的作用。